You are here: Industry Insights > AML

News List

Researchers identify new genetic target for acute myeloid leukaemia pharmatimes
May 07, 2021
Researchers from the Wellcome Sanger Institute have identified a new genetic target, which is linked with poor prognosis, for the potential treatment of acute myeloid leukaemia (AML) – a type of blood cancer.
Actinium Completes Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial americanpharmaceuticalreview
April 02, 2021
Actinium Pharmaceuticals announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia ...
ICR’s ‘resistance-busting’ drug advances into Phase I trial pharmatimes
March 19, 2021
The Institute of Cancer Research, London (ICR) has announced that its ‘resistance-busting’ drug EP0042 has entered a Phase I clinical trial in patients with cancers including acute myeloid leukaemia (AML).
Astellas Reports XOSPATA, Azacitidine Combination Did Not Meet Endpoint americanpharmaceuticalreview
December 23, 2020
Astellas Pharma announced that a Phase 3 trial of XOSPATA? (gilteritinib) plus azacitidine versus azacitidine alone in newly diagnosed FLT3 mutation-positive (FLT3mut+) acute myeloid leukemia (AML) patients who were ineligible for intensive induction ...
Syros acquires clinical-stage drug candidate for acute promyelocytic leukemia pharmaceutical-business-review
December 09, 2020
Syros Pharmaceuticals announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide (ATO).
Glycostem Initiates Trial to Evaluate oNKord for AML americanpharmaceuticalreview
December 08, 2020
Glycostem Therapeutics announced the opening of a phase I/IIa trial for its lead product oNKord? for the treatment of AML patients. The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries.
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China prnasia
December 07, 2020
I-Mab announced the advancement of clinical development of the highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4) in the US and China, achieving milestones as planned.
Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia prnasia
November 27, 2020
Golden Biotechnology Corp. announces that its new drug Antroquinonol (HOCENA?) outperforms the other listing drugs for the treatment of relapsed AML (acute myeloid leukemia) patients in its Phase 2 clinical study conducted in Russia.
Actimab-A CLAG-M Trial for Relapsed or Refractory AML Achieves 100% Remission Rate americanpharmaceuticalreview
November 13, 2020
Actinium Pharmaceuticals announced 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin (MCW) achieved remission.
Vor Biopharma signs exclusive license pact with NCI for clinical-stage CD33 CAR-T expresspharma
November 12, 2020
It is currently being evaluated in a multi-site Phase 1/2 clinical trial in children and young adults with relapsed or refractory acute myeloid leukemia (AML).